Article Text

Download PDFPDF
Letter response
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind randomised, placebo-controlled trial
  1. J-Y Reginster
  1. Correspondence to Professor J-Y Reginster, Bone and Cartilage Metabolism Unit, CHU Centre Ville, Unite dExploration du Metabolisme Osseux, Liège 4020, Belgium; jyreginster{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

I would like to reply to the recent letter by Murphy et al1 regarding the possible influence of obesity and weight changes on the results of the Strontium ranelate Efficacy in Knee Osteoarthritis trIAl (SEKOIA) trial of the efficacy and safety of strontium ranelate in knee osteoarthritis.2 Obesity and overweight are recognised risk factors for osteoarthritis,3 and so it is essential to include such patients in studies of potential treatments, since they are likely to constitute a substantial proportion of the patients who …

View Full Text


  • Competing interests JY Reginster has received consulting fees or paid advisory boards from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex; lecture fees when speaking at the invitation of a commercial sponsor from Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, Novo-Nordisk; grant support from Bristol Myers Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Eli Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, Servier.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles